Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects

BACKGROUND AND OBJECTIVES: GLPG0259 is a small-molecule inhibitor of mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5), a kinase enzyme that plays a role in important inflammatory pathways. The main objectives of the phase I clinical studies in early development were to characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Namour, Florence, Vanhoutte, Frédéric P., Beetens, Johan, Blockhuys, Stan, Weer, Marc De, Wigerinck, Piet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585965/
https://www.ncbi.nlm.nih.gov/pubmed/22950522
http://dx.doi.org/10.2165/11633120-000000000-00000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585965/
https://www.ncbi.nlm.nih.gov/pubmed/22950522
http://dx.doi.org/10.2165/11633120-000000000-00000

Ejemplares similares